Traws Pharma (NASDAQ:TRAW) Earns Neutral Rating from HC Wainwright

Traws Pharma (NASDAQ:TRAW)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports.

Several other equities analysts have also recently issued reports on TRAW. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, Citigroup cut Traws Pharma to a “neutral” rating in a research report on Monday. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Traws Pharma currently has a consensus rating of “Reduce” and an average price target of $8.00.

Traws Pharma Trading Down 4.5%

TRAW stock opened at $0.80 on Thursday. The stock has a market capitalization of $8.11 million, a PE ratio of -0.47 and a beta of 1.45. Traws Pharma has a 12-month low of $0.64 and a 12-month high of $3.27. The stock’s 50 day simple moving average is $1.44 and its 200 day simple moving average is $1.71.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.39. On average, research analysts predict that Traws Pharma will post -1.58 earnings per share for the current year.

Insider Buying and Selling at Traws Pharma

In other news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the stock in a transaction dated Thursday, April 16th. The shares were purchased at an average cost of $1.67 per share, with a total value of $998,207.43. Following the acquisition, the insider directly owned 1,203,250 shares of the company’s stock, valued at $2,009,427.50. This represents a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Traws Pharma

Several hedge funds and other institutional investors have recently modified their holdings of TRAW. State Street Corp bought a new position in shares of Traws Pharma during the 4th quarter valued at $29,000. Two Sigma Investments LP lifted its holdings in shares of Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after buying an additional 5,955 shares during the period. XTX Topco Ltd lifted its holdings in shares of Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after buying an additional 31,502 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of Traws Pharma during the 4th quarter valued at $56,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Traws Pharma by 41.9% during the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after buying an additional 18,213 shares during the period. 7.95% of the stock is owned by institutional investors.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.